Trial · NCT02625428
IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?
NCT02625428, Phase 4, Completed, Mayo Clinic; results first posted 2020-03-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys? Trials, record NCT02625428. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02625428
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?
- NCT number
- NCT02625428
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 40 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Transplantation, Kidney
- Interventions
- Optison, Ultrasound (US), Contrast-enhanced ultrasound (CEUS)
- First posted
- 2015-12-09
- Last updated
- 2020-03-02
- Results first posted
- 2020-03-02
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Abnormal Biopsy | 1 year | Number of subjects with abnormal biopsies in either the primary or secondary biopsy location, by diagnosis from a clinical pathologist |
| Secondary | Number of Patients With a Higher Degree of Renal Transplant Rejection Using Multiple Biopsies Compared to a Single Biopsy. | 1 year |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Abnormal Biopsy | 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients With a Higher Degree of Renal Transplant Rejection Using Multiple Biopsies Compared to a Single Biopsy. | 1 year | This outcome measure was not evaluated or analyzed as all subjects received multiple biopsies |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Abnormal Biopsy | For Cause | 10 | Participants | ||
| Abnormal Biopsy | Surveillance | 7 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | For Cause | 20 | |
| Overall Study | STARTED | Surveillance | 20 | |
| Overall Study | COMPLETED | For Cause | 20 | |
| Overall Study | COMPLETED | Surveillance | 20 | |
| Overall Study | NOT COMPLETED | For Cause | 0 | |
| Overall Study | NOT COMPLETED | Surveillance | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Major Bleeding Complications | Blood and lymphatic system disorders | For Cause | 2 | 20 | 2 |
| serious | Major Bleeding Complications | Blood and lymphatic system disorders | Surveillance | 1 | 20 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | For Cause | 0 | 20 |
| Total, all-cause mortality | Surveillance | 0 | 20 |
| Total, other adverse events | For Cause | 0 | 20 |
| Total, other adverse events | Surveillance | 0 | 20 |
| Total, serious adverse events | For Cause | 2 | 20 |
| Total, serious adverse events | Surveillance | 1 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| For Cause vs Surveillance: Abnormal Biopsy | Trial comparisons |
| For Cause vs Surveillance: deaths from any cause | Trial comparisons |
| For Cause vs Surveillance: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02625428
GET https://conductscience.org/api/trials/v1/NCT02625428/registered